Last reviewed · How we verify
Clostridium butyricum CBM588 Strain
Clostridium butyricum CBM588 Strain is a probiotic bacterium that may modulate the gut microbiome to exert therapeutic effects.
Clostridium butyricum CBM588 Strain is a probiotic bacterium that may modulate the gut microbiome to exert therapeutic effects. Used for Irritable bowel syndrome (IBS).
At a glance
| Generic name | Clostridium butyricum CBM588 Strain |
|---|---|
| Also known as | C. butyricum CBM588 Strain, C. butyricum MIYAIRI Strain, C. butyricum Strain MIYAIRI 588, CBM588, Clostridium butyricum MIYAIRI 588 |
| Sponsor | City of Hope Medical Center |
| Modality | Small molecule |
| Therapeutic area | Gastrointestinal |
| Phase | Phase 2 |
Mechanism of action
The exact mechanism of action of Clostridium butyricum CBM588 Strain is not fully understood, but it is thought to involve the production of butyrate, a short-chain fatty acid that has anti-inflammatory properties. This may lead to improved gut health and immune function, which could have therapeutic benefits in various conditions.
Approved indications
- Irritable bowel syndrome (IBS)
Common side effects
- Abdominal pain
- Diarrhea
Key clinical trials
- Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC (PHASE2)
- CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer (PHASE1)
- PAN-CLO-BU (PANcreas-CLOstridium-BUtyricum) (NA)
- Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer (PHASE3)
- Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery (PHASE2)
- CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant (PHASE1)
- CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer (PHASE1)
- CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clostridium butyricum CBM588 Strain CI brief — competitive landscape report
- Clostridium butyricum CBM588 Strain updates RSS · CI watch RSS
- City of Hope Medical Center portfolio CI